Latest news with #ICX
Time of India
24-07-2025
- Business
- Time of India
Power volumes up 14.9% in Q1; profit rises 25% to ₹120.7 crore
New Delhi: Electricity volumes traded at the Indian Energy Exchange (IEX) volumes traded in the first quarter of FY26 rose 14.9per cent year-on-year to 32.4 billion units (BUs), while consolidated profit after tax increased by 25.2per cent to ₹120.7 crore, the company said in its Q1 results released on July 24. Revenue during the quarter stood at ₹184.2 crore, up 19.2per cent compared to ₹154.5 crore in the corresponding quarter of FY25. Standalone profit after tax rose to ₹113 crore, up 21per cent from ₹93.4 crore in Q1FY25. The company reported that 52.7 lakh Renewable Energy Certificates (RECs) were traded in Q1FY26, marking a 149.3per cent increase over the previous year. Summer power demand peaks at 242 GW India's peak summer power demand in 2025 reached 242 GW on June 12. To manage this demand, the Ministry of Power invoked Section 11 of the Electricity Act, requiring imported coal-based power plants to operate at full capacity until June-end. The government also activated gas-based plants and ensured sufficient domestic coal supply to avert shortages. Despite forecasts projecting a peak demand of 277 GW, early monsoon and unseasonal rains kept temperatures low. As a result, electricity consumption for Q1FY26 was recorded at 446 BUs, down 1.3per cent from Q1FY25. Fuel supply steady; coal production at 247 MT Coal production during the first quarter stood at 247 million tonnes (MT), nearly the same as the year-ago period. Coal inventories in mid-July stood at 25 days' worth of supply, ensuring stable fuel availability for power generation. Increased availability from hydro, wind and coal-based generation contributed to higher liquidity on power exchanges. Day-Ahead Market (DAM) supply increased by 45.2per cent year-on-year. As a result, the average DAM price dropped nearly 16per cent to ₹4.41/unit, while the Real-Time Market price fell 20per cent to ₹3.91/unit. Gas market sees 109per cent volume growth Indian Gas Exchange (IGX) posted a 109per cent growth in traded volumes in Q1FY26, touching 24.6 million MMBtu, driven by increased demand from oil marketing companies and city gas distributors. IGX posted a PAT of ₹14.1 crore for the quarter, up 86.7per cent from ₹7.6 crore in Q1FY25. 44 lakh I-RECs issued by ICX in Q1 The International Carbon Exchange (ICX), a wholly owned subsidiary of the company, issued over 44 lakh International Renewable Energy Certificates (I-RECs) in Q1FY26, compared to 59 lakh for the full previous fiscal. ICX earned ₹178.8 lakh in revenue during the quarter. I-RECs are digital certificates representing the generation of 1 MWh of energy from renewable sources.
News18
24-07-2025
- Business
- News18
IEX net profit rises over 25 pc to Rs 121 cr in Jun qtr
Agency: New Delhi, Jul 24 (PTI) Indian Energy Exchange on Thursday posted an over 25 per cent rise in its consolidated net profit to Rs 120.69 crore in the June quarter compared to a year ago, mainly on the back of higher revenues. The company had reported a consolidated net profit of Rs 96.44 crore in the quarter ended on June 30, 2024, according to a regulatory filing. Total income rose to Rs 184.17 crore in the quarter from Rs 154.47 crore in the same period a year ago. Its electricity volumes in Q1FY26 stood at 32.4 billion units (BUs), increased 14.9 per cent year-on-year (YoY). The company said that 52.7 lakh renewable energy certificates (RECs) were traded during Q1FY26, jumping 149.3 per cent YoY. During the quarter, with an increase in hydro, wind and sustained supply from coal-based generation, supply liquidity on power exchanges improved and kept prices competitive. During the first quarter of FY26, supply liquidity in the Day Ahead Market (DAM) segment grew by 45.2 per cent on a year-on-year basis. As a result, the price in the DAM averaged Rs 4.41/unit, a decline of nearly 16 per cent YoY. On the gas market front, Indian Gas Exchange (IGX) traded record gas volumes of 24.6 million MMBtu during the period under review, a growth of 109 per cent from a year ago, led by a demand increase from oil marketing companies and city gas distribution companies. During the quarter, IGX recorded a profit after tax of Rs 14.1 crore, which was higher by nearly 86.7 per cent compared with Rs 7.6 crore a year ago. In the June quarter, its wholly-owned subsidiary International Carbon Exchange (ICX) issued over 44 lakh I-RECs against 59 lakh I-RECs issued in the last financial year. Revenue for ICX in the June quarter stood at Rs 178.8 lakh. The I-REC is a globally recognised digital certificate that serves as transferable proof of the generation of 1 MWh of energy from renewable sources. PTI KKS SHW view comments First Published: July 24, 2025, 18:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Yahoo
03-06-2025
- Business
- Yahoo
Oculis to Participate in Upcoming June Investor Conferences
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: ('Oculis'), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences: Goldman Sachs Annual Healthcare ConferenceJune 9-11; Miami, FL, chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET. J.P. Morgan European Healthcare Conference June 12; London, Sherif, MD, Chief Executive Officer, will be attending. The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section. -ENDS- About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis' highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: Oculis ContactsMs. Sylvia Cheung, Investor Relations LifeSci AdvisorsCorey Davis, Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous oculis@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
